Financhill
Buy
66

EXEL Quote, Financials, Valuation and Earnings

Last price:
$44.30
Seasonality move :
-0.47%
Day range:
$43.45 - $44.43
52-week range:
$21.82 - $49.62
Dividend yield:
0%
P/E ratio:
20.14x
P/S ratio:
5.62x
P/B ratio:
5.67x
Volume:
3.1M
Avg. volume:
3.3M
1-year change:
100%
Market cap:
$12.1B
Revenue:
$2.2B
EPS (TTM):
$2.20

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EXEL
Exelixis
$576.2M $0.63 -9.86% -18.7% $44.47
ADMA
ADMA Biologics
$122.1M $0.14 15.81% 7.69% $29.49
INCY
Incyte
$1.1B $1.40 10.06% 39.82% $75.15
INO
Inovio Pharmaceuticals
$10K -$0.63 -90.08% -46.85% $8.00
LCTX
Lineage Cell Therapeutics
$1.5M -$0.03 4.59% -- $3.92
VXRT
Vaxart
$2M -$0.10 -68.36% -5.56% $4.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EXEL
Exelixis
$44.30 $44.47 $12.1B 20.14x $0.00 0% 5.62x
ADMA
ADMA Biologics
$18.14 $29.49 $4.3B 21.34x $0.00 0% 9.67x
INCY
Incyte
$68.17 $75.15 $13.2B 213.03x $0.00 0% 3.16x
INO
Inovio Pharmaceuticals
$2.14 $8.00 $78.5M -- $0.00 0% --
LCTX
Lineage Cell Therapeutics
$1.02 $3.92 $232.9M -- $0.00 0% 22.52x
VXRT
Vaxart
$0.44 $4.67 $100M -- $0.00 0% 2.00x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EXEL
Exelixis
-- 0.463 -- 3.29x
ADMA
ADMA Biologics
16.26% -0.344 1.53% 3.20x
INCY
Incyte
-- 1.205 -- 1.88x
INO
Inovio Pharmaceuticals
-- 1.621 -- 2.55x
LCTX
Lineage Cell Therapeutics
-- 2.627 -- 3.68x
VXRT
Vaxart
-- 0.841 -- 0.59x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EXEL
Exelixis
$536.3M $186.9M 29.53% 29.53% 33.64% $189M
ADMA
ADMA Biologics
$61.1M $34.9M 57.3% 79.75% 30.86% -$24.4M
INCY
Incyte
$979.7M $216.7M 0.57% 0.57% 22.31% $262.9M
INO
Inovio Pharmaceuticals
-- -$25.1M -125.47% -125.47% -30140.49% -$26.9M
LCTX
Lineage Cell Therapeutics
$1.5M -$6.5M -22.68% -22.68% -433.09% -$5M
VXRT
Vaxart
-- -$14.9M -94.14% -94.14% -69.45% -$9.7M

Exelixis vs. Competitors

  • Which has Higher Returns EXEL or ADMA?

    ADMA Biologics has a net margin of 28.74% compared to Exelixis's net margin of 23.44%. Exelixis's return on equity of 29.53% beat ADMA Biologics's return on equity of 79.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXEL
    Exelixis
    96.55% $0.55 $2.1B
    ADMA
    ADMA Biologics
    53.22% $0.11 $445.9M
  • What do Analysts Say About EXEL or ADMA?

    Exelixis has a consensus price target of $44.47, signalling upside risk potential of 0.39%. On the other hand ADMA Biologics has an analysts' consensus of $29.49 which suggests that it could grow by 62.57%. Given that ADMA Biologics has higher upside potential than Exelixis, analysts believe ADMA Biologics is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXEL
    Exelixis
    8 8 0
    ADMA
    ADMA Biologics
    2 1 0
  • Is EXEL or ADMA More Risky?

    Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.691%.

  • Which is a Better Dividend Stock EXEL or ADMA?

    Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXEL or ADMA?

    Exelixis quarterly revenues are $555.4M, which are larger than ADMA Biologics quarterly revenues of $114.8M. Exelixis's net income of $159.6M is higher than ADMA Biologics's net income of $26.9M. Notably, Exelixis's price-to-earnings ratio is 20.14x while ADMA Biologics's PE ratio is 21.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.62x versus 9.67x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXEL
    Exelixis
    5.62x 20.14x $555.4M $159.6M
    ADMA
    ADMA Biologics
    9.67x 21.34x $114.8M $26.9M
  • Which has Higher Returns EXEL or INCY?

    Incyte has a net margin of 28.74% compared to Exelixis's net margin of 15.03%. Exelixis's return on equity of 29.53% beat Incyte's return on equity of 0.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXEL
    Exelixis
    96.55% $0.55 $2.1B
    INCY
    Incyte
    93.05% $0.80 $3.7B
  • What do Analysts Say About EXEL or INCY?

    Exelixis has a consensus price target of $44.47, signalling upside risk potential of 0.39%. On the other hand Incyte has an analysts' consensus of $75.15 which suggests that it could grow by 10.23%. Given that Incyte has higher upside potential than Exelixis, analysts believe Incyte is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXEL
    Exelixis
    8 8 0
    INCY
    Incyte
    9 15 1
  • Is EXEL or INCY More Risky?

    Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Incyte has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.054%.

  • Which is a Better Dividend Stock EXEL or INCY?

    Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXEL or INCY?

    Exelixis quarterly revenues are $555.4M, which are smaller than Incyte quarterly revenues of $1.1B. Exelixis's net income of $159.6M is higher than Incyte's net income of $158.2M. Notably, Exelixis's price-to-earnings ratio is 20.14x while Incyte's PE ratio is 213.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.62x versus 3.16x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXEL
    Exelixis
    5.62x 20.14x $555.4M $159.6M
    INCY
    Incyte
    3.16x 213.03x $1.1B $158.2M
  • Which has Higher Returns EXEL or INO?

    Inovio Pharmaceuticals has a net margin of 28.74% compared to Exelixis's net margin of -30140.49%. Exelixis's return on equity of 29.53% beat Inovio Pharmaceuticals's return on equity of -125.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXEL
    Exelixis
    96.55% $0.55 $2.1B
    INO
    Inovio Pharmaceuticals
    -- -$0.51 $51.3M
  • What do Analysts Say About EXEL or INO?

    Exelixis has a consensus price target of $44.47, signalling upside risk potential of 0.39%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $8.00 which suggests that it could grow by 273.83%. Given that Inovio Pharmaceuticals has higher upside potential than Exelixis, analysts believe Inovio Pharmaceuticals is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXEL
    Exelixis
    8 8 0
    INO
    Inovio Pharmaceuticals
    2 2 0
  • Is EXEL or INO More Risky?

    Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 1.307, suggesting its more volatile than the S&P 500 by 30.734%.

  • Which is a Better Dividend Stock EXEL or INO?

    Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXEL or INO?

    Exelixis quarterly revenues are $555.4M, which are larger than Inovio Pharmaceuticals quarterly revenues of $65.3K. Exelixis's net income of $159.6M is higher than Inovio Pharmaceuticals's net income of -$19.7M. Notably, Exelixis's price-to-earnings ratio is 20.14x while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.62x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXEL
    Exelixis
    5.62x 20.14x $555.4M $159.6M
    INO
    Inovio Pharmaceuticals
    -- -- $65.3K -$19.7M
  • Which has Higher Returns EXEL or LCTX?

    Lineage Cell Therapeutics has a net margin of 28.74% compared to Exelixis's net margin of -275.57%. Exelixis's return on equity of 29.53% beat Lineage Cell Therapeutics's return on equity of -22.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXEL
    Exelixis
    96.55% $0.55 $2.1B
    LCTX
    Lineage Cell Therapeutics
    97.6% -$0.02 $77.7M
  • What do Analysts Say About EXEL or LCTX?

    Exelixis has a consensus price target of $44.47, signalling upside risk potential of 0.39%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 283.99%. Given that Lineage Cell Therapeutics has higher upside potential than Exelixis, analysts believe Lineage Cell Therapeutics is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXEL
    Exelixis
    8 8 0
    LCTX
    Lineage Cell Therapeutics
    4 1 0
  • Is EXEL or LCTX More Risky?

    Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.603, suggesting its more volatile than the S&P 500 by 60.322%.

  • Which is a Better Dividend Stock EXEL or LCTX?

    Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXEL or LCTX?

    Exelixis quarterly revenues are $555.4M, which are larger than Lineage Cell Therapeutics quarterly revenues of $1.5M. Exelixis's net income of $159.6M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, Exelixis's price-to-earnings ratio is 20.14x while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.62x versus 22.52x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXEL
    Exelixis
    5.62x 20.14x $555.4M $159.6M
    LCTX
    Lineage Cell Therapeutics
    22.52x -- $1.5M -$4.1M
  • Which has Higher Returns EXEL or VXRT?

    Vaxart has a net margin of 28.74% compared to Exelixis's net margin of -74.68%. Exelixis's return on equity of 29.53% beat Vaxart's return on equity of -94.14%.

    Company Gross Margin Earnings Per Share Invested Capital
    EXEL
    Exelixis
    96.55% $0.55 $2.1B
    VXRT
    Vaxart
    -- -$0.07 $45.6M
  • What do Analysts Say About EXEL or VXRT?

    Exelixis has a consensus price target of $44.47, signalling upside risk potential of 0.39%. On the other hand Vaxart has an analysts' consensus of $4.67 which suggests that it could grow by 965.45%. Given that Vaxart has higher upside potential than Exelixis, analysts believe Vaxart is more attractive than Exelixis.

    Company Buy Ratings Hold Ratings Sell Ratings
    EXEL
    Exelixis
    8 8 0
    VXRT
    Vaxart
    3 0 0
  • Is EXEL or VXRT More Risky?

    Exelixis has a beta of 0.283, which suggesting that the stock is 71.722% less volatile than S&P 500. In comparison Vaxart has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.422%.

  • Which is a Better Dividend Stock EXEL or VXRT?

    Exelixis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vaxart offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exelixis pays -- of its earnings as a dividend. Vaxart pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EXEL or VXRT?

    Exelixis quarterly revenues are $555.4M, which are larger than Vaxart quarterly revenues of $20.9M. Exelixis's net income of $159.6M is higher than Vaxart's net income of -$15.6M. Notably, Exelixis's price-to-earnings ratio is 20.14x while Vaxart's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exelixis is 5.62x versus 2.00x for Vaxart. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EXEL
    Exelixis
    5.62x 20.14x $555.4M $159.6M
    VXRT
    Vaxart
    2.00x -- $20.9M -$15.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Why Is Goldman Sachs Stock Up So Much?
Why Is Goldman Sachs Stock Up So Much?

Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 17.29% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 0.03% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock